Anthropic has added Vas Narasimhan, the chief executive of Swiss drugmaker Novartis, to its board of directors, a development reported on Tuesday by the Wall Street Journal. The appointment represents the companys second board expansion in recent months as it positions itself for growth and potential public markets activity.
Earlier this year Anthropic appointed Chris Liddell, a former executive at Microsoft and General Motors, to its board in February. The company has framed these board changes as part of broader governance strengthening while it evaluates an initial public offering - potentially as soon as this year - and broadens its enterprise-focused efforts, particularly in healthcare.
Healthcare has emerged as a strategic priority for the Claude chatbot developer. Anthropic has entered partnerships with pharmaceutical companies including Eli Lilly, Novo Nordisk and Genmab. The stated objective of these collaborations is to shorten drug development life cycles, bringing AI capabilities to bear on processes that pharmaceutical partners view as time- and resource-intensive.
In a statement cited by Anthropic co-founder Daniela Amodei, Narasimhan was noted for overseeing the development and approval of more than 35 novel medicines in "one of the most regulated industries." The company highlighted that Narasimhans experience in highly regulated drug development environments adds relevant expertise as Anthropic steps up its engagement with healthcare customers.
The board additions come as Anthropic balances corporate governance adjustments with commercial ambitions. Strengthening its board is being presented as part of the companys preparatory work ahead of a potential IPO and an intensified enterprise push into health-related markets.
Details on the terms of Narasimhans appointment, including any changes to board composition beyond the recently announced additions, were not disclosed in the report. Nor were specifics provided about timing or structure of any potential initial public offering beyond the indication that it could occur as soon as this year.
Partnerships highlighted in reporting:
- Eli Lilly
- Novo Nordisk
- Genmab